Navigation Links
Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
Date:1/8/2009

MONTREAL, Jan. 8 /PRNewswire/ - Aegera Therapeutics Inc. announced today the dosing of the first patient in a randomized Phase 2 study of AEG35156, their targeted antisense therapeutic in mid-stage development for multiple oncology indications.

The study, entitled "A Phase 2, Multicenter, Open-Label, Randomized Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given In Combination With Carboplatin/Paclitaxel or the Combination of Carboplatin/Paclitaxel Alone In Patients With Advanced Non Small Cell Lung Cancer" is being conducted in the United States in collaboration with U.S. Oncology and additional sites will be opened in Canada. The Principal Investigator of this study is Dr. Robert M. Jotte, of the Rocky Mountain Cancer Center in Denver, Colorado.

The primary objective of this study is to compare the efficacy of the standard of care for this patient population to the standard of care in combination with AEG35156. Recruitment for this trial is expected to be completed prior to the end of 2009.

"Preliminary evidence of activity was observed in the Phase 1 portion of this study and encouraged us to amend the clinical protocol to provide for a control arm for the Phase 2 portion of the study" stated Dr. Jacques Jolivet, Senior Vice-President of Clinical Development of Aegera.

"Our clinical program around AEG35156 continues to accelerate and expand as we seek to move this therapeutic forward to more advanced stages of clinical development," added Aegera's President and Chief Executive Officer, Dr. Michael J. Berendt. "The initiation of this randomized Phase 2 study in lung cancer follows very shortly after our publication of positive clinical data from our Phase 1/2 study in AML at the recent ASH conference in San Francisco and represents the first of multiple new clinical trials for this innovative therapy that we hope to announce over the course of 2009."

About AEG35156

Cancer cells acquire multiple mutations that disable their normal response to apoptotic triggers. AEG35156, a second generation antisense which targets XIAP, is designed to lower the apoptotic threshold of cancer cells, enhancing their sensitivity to intrinsic death and chemotherapy, without harming healthy cells. Aegera's published data with AEG35156, both in vitro and in vivo, strongly supports this hypothesis, and validates XIAP as a novel drug target for the development of anti-cancer therapeutics.

About Aegera Therapeutics Inc.

Aegera Therapeutics is a clinical stage biotechnology company focused on developing novel targeted therapies that address major unmet medical needs. In addition to AEG35156, Aegera has two additional programs in clinical development for the treatment of cancer and neuropathic pain. Details of these programs can be found on Aegera's website at www.aegera.com.


'/>"/>
SOURCE AEGERA THERAPEUTICS INC.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Aegera Therapeutics phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
2. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
3. Aegera Therapeutics welcomes two experienced executives to its board of directors
4. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
5. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
6. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
7. Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market
8. Horizon Therapeutics Announces Senior Management Appointments
9. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
10. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
11. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Researchers at ... most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the ... read it now. , Diagnostic biomarkers are signposts in the blood, lung fluid ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... to announce the launch of their brand, UP4™ Probiotics, into Target stores nationwide. ... years, is proud to add Target to its list of well-respected retailers. This ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... , June 23, 2016 Houston Methodist ... the Cy-Fair Sports Association to serve as their ... agreement, Houston Methodist Willowbrook will provide sponsorship support, ... connectivity with association coaches, volunteers, athletes and families. ... the Cy-Fair Sports Association and to bring Houston ...
Breaking Biology Technology:
(Date:6/21/2016)... British Columbia , June 21, 2016 /PRNewswire/ ... appointed to the new role of principal product ... been named the director of customer development. Both ... NuData,s chief technical officer. The moves reflect NuData,s ... teams in response to high customer demand and ...
(Date:6/9/2016)... 2016 Paris Police Prefecture ... security solution to ensure the safety of people and operations ... the major tournament Teleste, an international technology group ... announced today that its video security solution will be utilised ... up public safety across the country. The system roll-out is ...
(Date:6/2/2016)... Perimeter Surveillance & Detection Systems, ... Infrastructure, Support & Other Service  The latest ... comprehensive analysis of the global Border Security market ... of $17.98 billion in 2016. Now: In ... in software and hardware technologies for advanced video surveillance. ...
Breaking Biology News(10 mins):